List of Excipients in Branded Drug DYAZIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
GlaxoSmithKline LLC	DYAZIDE	hydrochlorothiazide and triamterene	0007-3650	BENZYL ALCOHOL
GlaxoSmithKline LLC	DYAZIDE	hydrochlorothiazide and triamterene	0007-3650	CELLULOSE, MICROCRYSTALLINE
GlaxoSmithKline LLC	DYAZIDE	hydrochlorothiazide and triamterene	0007-3650	CETYLPYRIDINIUM CHLORIDE

Dyazide Excipient Strategy and Commercial Opportunities

Last updated: August 25, 2026

Dyazide is a fixed-dose oral combination of triamterene and hydrochlorothiazide, commonly supplied as a capsule containing 37.5 mg of triamterene and 25 mg of hydrochlorothiazide. Its commercial opportunity is primarily generic substitution, formulation improvement, and supply-chain differentiation rather than new-molecule exclusivity. The strongest excipient strategy focuses on dose uniformity, dissolution control, moisture protection, capsule compatibility, and lower-cost manufacturing. [1][2]

What is Dyazide and how does its formulation create excipient opportunities?

Dyazide combines a potassium-sparing diuretic, triamterene, with the thiazide diuretic hydrochlorothiazide. The combination is used for hypertension and edema when potassium conservation is clinically relevant. [1]

The formulation presents several technical challenges:

Formulation issue	Commercial relevance	Excipient response
Two active ingredients with different physicochemical properties	Increases content-uniformity risk	Separate premixes, controlled granulation, validated blending
Low-dose triamterene relative to total fill weight	Raises potency and segregation concerns	Geometric dilution, carrier selection, low-shear blending
Immediate-release performance requirement	Dissolution failure can delay approval or trigger recalls	Disintegrant and wetting-agent optimization
Moisture sensitivity and capsule-shell interaction	Can affect stability and appearance	Moisture-barrier packaging, controlled water activity
Color and product-identification requirements	Supports product differentiation and error reduction	Colorants, imprinting, capsule-shell alternatives
Combination-product bioequivalence	Requires matching in-vitro and in-vivo performance	Excipient levels should remain within a robust design space

Dyazide is not an extended-release product. A generic manufacturer therefore does not need to reproduce a complex controlled-release matrix, osmotic system, or modified-release coating. The principal challenge is reproducing the reference product's release behavior while maintaining reliable manufacturing at commercial scale.

What excipients are used in Dyazide capsules?

The exact inactive-ingredient profile depends on the reference product, manufacturer, strength, and market. FDA labeling and DailyMed should be used as the controlling sources for a specific product presentation. Public labeling for triamterene/hydrochlorothiazide capsules identifies conventional oral-solid-dose excipient classes, including fillers, binders, disintegrants, lubricants, capsule-shell materials, and colorants. [1][2]

A generic development team should treat the reference formulation as a performance target rather than assume that every listed excipient must be copied. Under the FDA abbreviated new drug application pathway, the proposed product may use different inactive ingredients if it meets safety, quality, bioequivalence, and labeling requirements. FDA's Inactive Ingredient Database can support regulatory acceptability assessments, but it does not replace product-specific toxicology, compatibility, or process validation. [3]

Which excipient classes are most relevant?

Fillers and carriers

Lactose, microcrystalline cellulose, dibasic calcium phosphate, and starch-based carriers may be considered depending on blend density, compressibility, and capsule-fill requirements. Lactose may create development concerns for manufacturers seeking lactose-free positioning or for products using moisture-sensitive actives.

Microcrystalline cellulose can improve blend handling and capsule-fill consistency. Dibasic calcium phosphate can provide density and flow but may alter dissolution or create compatibility concerns with certain formulation components. Selection should be based on the finished-product performance profile rather than unit cost alone.

Binders and granulation aids

Povidone, hydroxypropyl cellulose, and starch-based binders may improve granule strength and reduce segregation. Excessive binder concentration can slow disintegration and dissolution, which is material for an immediate-release combination product.

A dry-granulation or direct-fill process may reduce solvent exposure and manufacturing complexity. Wet granulation may provide better control of low-dose triamterene distribution but adds drying and residual-moisture controls.

Disintegrants

Croscarmellose sodium, crospovidone, and sodium starch glycolate are potential disintegrant platforms. The preferred choice depends on particle size, granule porosity, lubricant concentration, and target dissolution. Crospovidone may be useful where rapid wicking and low swelling are preferred. Sodium starch glycolate can provide strong swelling but may be more sensitive to over-granulation or excessive compression.

Lubricants and glidants

Magnesium stearate is widely used in oral solid dosage forms, but over-lubrication can create a hydrophobic film and slow dissolution. Colloidal silicon dioxide may improve flow, but its level must be controlled to avoid powder segregation or capsule-fill variability.

Capsule-shell materials and colorants

Hard gelatin capsules are conventional for this product class. Hypromellose capsules may support vegetarian, religious, or supply-chain positioning, although shell substitution requires evaluation of moisture transfer, mechanical strength, dissolution, and stability.

Colorants can support brand recognition and reduce medication-selection errors. They also create regulatory and supply risks because colorant availability, regional approvals, and customer preferences can change. A color-free or mineral-pigment strategy may reduce those risks but would remove a visual differentiation tool.

How should a manufacturer design an excipient strategy for generic Dyazide?

The highest-value development approach is a quality-by-design program built around critical material attributes and critical process parameters.

Control triamterene distribution

Triamterene is present at a lower dose than hydrochlorothiazide. Low-dose distribution is therefore a central development risk. A manufacturer should evaluate:

• Particle-size distribution of both active ingredients
• Density differences between actives and excipients
• Blend segregation during transfer and capsule filling
• Granulation endpoint and granule-size distribution
• Blend uniformity after lubrication
• Hold-time effects before encapsulation

A separate triamterene premix diluted with a selected carrier can improve content uniformity. The carrier should have a compatible particle-size distribution and similar flow behavior.

Match dissolution without copying the full excipient system

Dissolution should be assessed for each active independently and for the combined product. A formulation that releases hydrochlorothiazide rapidly but retains triamterene may produce an unacceptable profile even if total drug release appears adequate.

Screening should cover:

• Disintegrant type and concentration
• Lubrication time
• Granule porosity
• Wetting-agent concentration
• Capsule-shell type
• Media pH and agitation conditions
• Fed and fasted performance where relevant

The objective is a robust formulation with adequate dissolution across normal process variation, not a formulation that passes only at the nominal operating point.

Use excipients to lower manufacturing cost

The most commercially attractive process is usually the one that reduces variability without requiring specialized equipment. Direct blending and capsule filling can lower capital requirements, but only if low-dose uniformity and segregation are controlled. Dry granulation may provide a middle path between direct fill and wet granulation.

Cost modeling should include:

• Excipient price and supply concentration
• Yield loss
• Granulation and drying time
• Cleaning requirements
• Batch-release testing
• Packaging-barrier requirements
• Stability failures and rework
• Multiple-source qualification

An inexpensive excipient that increases dissolution variability or batch rejection can reduce total margin.

What formulation patents protect Dyazide?

The original fixed-dose combination is an established product, and the principal composition-of-matter and early formulation exclusivity periods have expired. Current generic competition is therefore governed primarily by FDA approval requirements, manufacturing capability, product quality, and market economics rather than active pioneer patent protection. [1][4]

Protection category	Dyazide commercial position
Active ingredients	Long-expired composition protection
Fixed-dose combination	No meaningful current pioneer exclusivity barrier identified
Immediate-release capsule	Established dosage form with generic precedent
Formulation patents	Any surviving claims would require product-specific patent and jurisdiction review
Method-of-use patents	Historical use claims would generally be expired or commercially weak
FDA exclusivity	No current new-drug exclusivity expected for the established product
Orange Book patents	Current status must be checked against the FDA Orange Book for the exact reference listing

The absence of a strong current patent barrier does not eliminate litigation risk. A generic applicant can still face patent litigation if an Orange Book-listed patent is asserted, or if the applicant's formulation, labeling, manufacturing process, or method-of-use raises a separate claim. A Paragraph IV certification would be relevant only if an unexpired, listed patent covered the reference product or an approved use. [4][5]

When does Dyazide lose exclusivity?

Dyazide's meaningful market exclusivity ended long ago. The product is now an established generic combination rather than a protected growth product. The relevant commercial question is not the loss date of the original exclusivity but whether a new manufacturer can obtain approval at a cost that supports sustainable pricing.

FDA approval is generally pursued through an ANDA demonstrating pharmaceutical equivalence and bioequivalence to the reference listed drug. The applicant must also satisfy current requirements for chemistry, manufacturing, controls, stability, labeling, and facility compliance. [5]

What is the Orange Book status of Dyazide?

The Orange Book identifies FDA-approved reference listed drugs and relevant patent and exclusivity information. For Dyazide and triamterene/hydrochlorothiazide products, the sponsor should verify the exact reference listing, dosage form, strength, therapeutic equivalence codes, and any active patent entries before filing or acquiring a product. [4]

Because the product has a long generic history, the main Orange Book value is product-selection and regulatory benchmarking:

• Confirm the correct reference listed drug.
• Confirm capsule strength and dosage form.
• Review therapeutic-equivalence ratings for competing products.
• Check current patent certifications.
• Determine whether any listed patent affects labeling or launch timing.

What generic entry risks exist for Dyazide?

Generic entry risk is high because the active ingredients are old, the dosage form is conventional, and multiple manufacturers can potentially supply the market. Price erosion is the principal commercial risk.

A new entrant faces five main barriers:

1. Bioequivalence failure caused by excipient-driven dissolution differences.
2. Inability to achieve low-dose triamterene uniformity at scale.
3. Supply interruptions for capsule shells, colorants, or specialty excipients.
4. Limited market size relative to ANDA development and maintenance costs.
5. Contract-manufacturing competition from established suppliers.

The product may still be attractive where a manufacturer has underused encapsulation capacity, an established diuretic portfolio, or a differentiated supply proposition.

Which excipient-led commercial opportunities exist?

Lactose-free or allergen-positioned capsules

A lactose-free formulation could target hospitals, wholesalers, and patients who prefer to avoid lactose. The opportunity is commercial rather than therapeutic and would require disciplined labeling because excipient-free claims must be accurate and jurisdiction-specific.

Vegetarian or HPMC capsules

Hypromellose shells could differentiate the product for institutional procurement and selected retail channels. The opportunity is strongest if the manufacturer can maintain equivalent dissolution and stable supply.

Improved moisture protection

A high-barrier blister or desiccant-based bottle can reduce stability risk. Packaging is not an excipient, but it can expand the usable excipient design space by reducing moisture exposure. This may allow a lower-cost formulation without sacrificing shelf life.

Colorant-free products

A colorant-free capsule may appeal to customers seeking simpler excipient profiles. The tradeoff is reduced visual differentiation and greater dependence on imprinting, packaging controls, and pharmacy-level verification.

Regional excipient platforms

A manufacturer can use one core formulation with region-specific capsule shells or color systems. This reduces development duplication while accommodating local excipient restrictions and procurement requirements.

Combination-product manufacturing platforms

A validated process for triamterene/hydrochlorothiazide can support adjacent opportunities in older fixed-dose cardiovascular and diuretic combinations. The commercial value increases when equipment, analytical methods, and suppliers are shared across several products.

How strong is the Dyazide patent estate?

The patent estate is commercially weak relative to newer branded medicines. The active ingredients and combination have been marketed for decades, and the principal opportunity lies in operational execution. Any residual risk is more likely to arise from formulation-specific claims, supplier-owned technology, manufacturing know-how, or regulatory deficiencies than from a broad blocking patent.

Patent diligence should still cover:

• Current Orange Book entries
• Expired and unexpired formulation patents
• Patent assignments and terminal disclaimers
• Litigation involving triamterene/hydrochlorothiazide products
• Supplier agreements covering coated particles, specialty capsules, or analytical methods
• Freedom to operate in the United States, Europe, Canada, and other target markets

What is the revenue opportunity for Dyazide?

Product-level revenue data for Dyazide are generally less transparent than company-level sales for major branded drugs. The product is mature, genericized, and exposed to price competition. Revenue potential depends on:

• Market share captured from incumbent ANDA holders
• Wholesale acquisition price
• Number of competing suppliers
• Formulation and packaging cost
• Reimbursement status
• Contract access
• Shortage conditions
• Institutional versus retail channel mix

A differentiated excipient strategy is unlikely to support a large premium by itself. It can support preferred-supplier status when it improves supply continuity, simplifies procurement, addresses excipient restrictions, or reduces quality complaints.

Key Takeaways

• Dyazide is a mature triamterene/hydrochlorothiazide fixed-dose capsule with no meaningful pioneer exclusivity barrier.
• The main formulation risk is uniform distribution of low-dose triamterene, followed by dissolution and moisture control.
• Excipients should be selected for process robustness, not merely reference-product imitation.
• Lactose-free, HPMC-capsule, color-free, and high-barrier-packaging variants offer the clearest commercial differentiation.
• Generic entry risk is high because the dosage form is conventional and the product has long-standing generic precedent.
• The strongest commercial case is a low-cost, reliable formulation produced by a manufacturer with existing encapsulation and analytical infrastructure.
• Orange Book, DailyMed, FDA inactive-ingredient, and patent-assignment reviews remain necessary before a product-specific launch decision.

FAQs

Can Dyazide be reformulated as a tablet?

Yes, a tablet may be technically feasible, but it would require a separate pharmaceutical-equivalence and bioequivalence strategy. A tablet would not automatically qualify as the same dosage form as a capsule and could face different reference-product and regulatory requirements.

Is a sustained-release Dyazide product commercially attractive?

Potentially, but it would be a new formulation strategy rather than a straightforward generic substitute. Sustained release would require new pharmacokinetic, dissolution, stability, and clinical or regulatory justification and would face greater development cost.

Can a generic manufacturer use different excipients from Dyazide?

Yes. FDA permits inactive-ingredient differences when the proposed product meets applicable safety, quality, labeling, and bioequivalence requirements. The proposed excipients must also be suitable for the intended route, dose, and dosage form. [3][5]

Do capsule color and shell composition affect generic approval?

They can. Capsule-shell composition, colorants, imprinting, moisture transfer, dissolution, and stability may affect product quality and labeling. Changes should be evaluated through comparative quality and stability studies.

Is a Dyazide excipient patent likely to block generic entry?

A broad blocking patent is unlikely for the established product. The more relevant risks are product-specific formulation claims, manufacturing patents, supplier restrictions, and FDA deficiencies.

References

1. U.S. Food and Drug Administration. (n.d.). Dyazide: Triamterene and hydrochlorothiazide capsule prescribing information. DailyMed.

2. National Library of Medicine. (n.d.). DailyMed: Triamterene and hydrochlorothiazide capsule drug labels. U.S. National Library of Medicine.

3. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

5. U.S. Food and Drug Administration. (2014). Abbreviated new drug application submissions: Content and format of an ANDA. FDA guidance and regulatory resources.